All News
RA Patients on Biologics and tsDMARDs are still High Risk
A new Swedish ARTIS registry study of key safety outcomes in rheumatoid arthritis (RA) patients receiving either targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs, including Janus Kinase inhibitors (JAKi)), has been updated and affirms previously held risks.
Read Article
Best Treatments for Immune Checkpoint Inhibitor-associated Arthritis
A retrospective study of cancer patients who developed immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) shows that biologic DMARDs were more effective than conventional synthetic DMARDs (csDMARDs) in rapid control of arthritis.
Read Article
Clinical Profile of RA-associated Interstitial Lung Disease
A prospective, cross-sectional analysis of patients with rheumatoid arthritis (RA) shows those with interstitial lung disease (ILD) tend to be older, obese and have a smoking history.
Read Article
Industry Payments to Rheumatologists Dropped During COVID
Having their clinics shut down and patients staying away during the COVID-19 pandemic was bad enough for physicians' finances, but now a new study finds that, at least for rheumatologists, payments from industry dried up as well.
Read Article
“You Can Have it All” (4.7.2023)
Dr. Jack Cush reviews the news and highlights from our "Women in Rheumatology" Campaign from last week on RheumNow.com
Read Article
Steroid-Sparing Rituximab in Polymyalgia Rheumatica
BRIDGE-PMR proof-of-concept trial assessed the efficacy of rituximab (RTX) in patients with polymyalgia rheumatica (PMR) and showed that a single 1000 mg dose of lead to a significant number of glucocorticoid-free remissions after 1 year.
Read Article
British Society of Rheumatology Plans Revision of Systemic Sclerosis Guideline
British Society for Rheumatology (BSR) last published its guideline for systemic sclerosis (SSc) in 2016. Given the many advances in the field the BSR has outlined their plans to update the management of SSc.
Read Article
EMA Final Update on JAK Inhibitors and MACE, Malignancy & VTE Risks
The EMA has updated recommendations regarding the use of JAK inhibitors by issuing a direct healthcare professional communication summarizing the data and warnings regarding an increased risk of malignancy, major adverse cardiovascular events (MACE), serious infections, VTE, and mortality in some patients receiving JAKi for the treatment of chronic inflammatory disorders.
Read Article
Intrathecal Methotrexate for Cerebritis (3.31.2023)
Dr. Jack Cush reviews the CV advantage to walking, the OA risk with running and the eczema-OA connection; these articles and journal reports from the past week on RheumNow.com.
Read Article
Alcohol Differences in Urate Level Elevation
Does serum urate elevation differ with different types of alcohol consumption? A Japanese study shows beer and wine was associated with high and moderate increases in uric acid but less so with sake.
Read Article
Gout - Hot Topics in March 2023
A number of new reports this month shed new light on old issues in Gout.
Read Article
Atopic Disease Increases Osteoarthritis Risk
Analysis of commercial insurance claims suggests that patients with asthma or atopic dermatitis have a significantly increased risk of osteoarthritis.
Read Article
LAVLI - A New Autoinflammatory Disorder
NIH researchers have have described a novel autoinflammatory disorder called "Lyn kinase-associated vasculopathy and liver fibrosis" (LAVLI), based on a mutation in the LYN gene (that encodes the Lyn kinase protein).
Read Article
Docs' Liking for Knee Injection Tied to Industry Payments
Physicians accepting payments from drug and device companies administered significantly more hyaluronic acid (HA) injections to Medicare beneficiaries for knee osteoarthritis, researchers found.
Read Article
Links:
Links:
Links:
Links:
Links:
Links:
